Similar reduction in activated MEK/ERK proteins were also observed in tetracyclin-induced EGFRvIII-positive U251-E18 (Supplementary Fig. 4g) and EGFRvIII-positive GBM patient-derived primary cells (Supplementary Fig. 4h). The gene discussed is MAP2K7; the disease is glioblastoma.